Journal: BioMed Research International

Article Title: Identification of Key Genes in the Response to Salmonella enterica Enteritidis , Salmonella enterica Pullorum , and Poly(I:C) in Chicken Spleen and Caecum

doi: 10.1155/2014/154946

Figure Lengend Snippet: qRT-PCR results of five DEGs selected from microarray data. ( P value ≤ 0.05).

Article Snippet: Subsequently, spleen and caecum samples of four individuals from each group with intact experimental records were randomly selected and sent to Shanghai Biotechnology Co., Ltd. (SBC), which performed the microarray test.

Techniques: Microarray, Expressing

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

Techniques: Microarray, Comparison

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

Techniques: Comparison, Microarray

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

Techniques: Comparison, Microarray

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

Techniques: Comparison, Microarray

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Test search with the according keywords (trade name, gene(s), NGS application, validity or validation) on the basis of the FDA list “Nucleic acid-based tests” focusing on the category “drug metabolizing enzymes”

Article Snippet: CYP2C19 , Spartan RX CYP2C19 Test System/ Microarray , Akonni Biosystems Inc..

Techniques: Biomarker Discovery, Luminex, Multiplex Assay, Flow Cytometry, Microarray, Genotyping Assay, Hybridization

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Test search results with the according keywords (trade name, gene(s), NGS application, validity or validation). All findings for second generation sequencing (SGS) including targeted NGS, WES and WGS and for third generation sequencing (TGS) were summed up excluding duplications. The number of according publications providing performance evaluations was included in brackets.

Article Snippet: CYP2C19 , Spartan RX CYP2C19 Test System/ Microarray , Akonni Biosystems Inc..

Techniques: Biomarker Discovery, Sequencing, Multiplex Assay, Flow Cytometry, Luminex, Microarray, Genotyping Assay, Hybridization

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Publications identified in the second literature search reporting approaches of analytical validation or concordance evaluation of NGS-based tests

Article Snippet: CYP2C19 , Spartan RX CYP2C19 Test System/ Microarray , Akonni Biosystems Inc..

Techniques: Biomarker Discovery, Sequencing

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Overview of publications evaluating genetic tests based on second and third generation sequencing that include the according pharmacogenes of interest

Article Snippet: CYP2C19 , Spartan RX CYP2C19 Test System/ Microarray , Akonni Biosystems Inc..

Techniques: Sequencing

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Test search with the according keywords (trade name, gene(s), NGS application, validity or validation) on the basis of the FDA list “Nucleic acid-based tests” focusing on the category “drug metabolizing enzymes”

Article Snippet: CYP2C9, VKORC1 , TruDiagnosis System, TruArray® Warfarin Sensitivity Test Kit/Microarray , Akonni Biosystems Inc , - , - , No.

Techniques: Biomarker Discovery, Luminex, Multiplex Assay, Flow Cytometry, Microarray, Genotyping Assay, Hybridization

Journal: Molecular Biology Reports

Article Title: Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling

doi: 10.1007/s11033-023-08748-z

Figure Lengend Snippet: Test search results with the according keywords (trade name, gene(s), NGS application, validity or validation). All findings for second generation sequencing (SGS) including targeted NGS, WES and WGS and for third generation sequencing (TGS) were summed up excluding duplications. The number of according publications providing performance evaluations was included in brackets.

Article Snippet: CYP2C9, VKORC1 , TruDiagnosis System, TruArray® Warfarin Sensitivity Test Kit/Microarray , Akonni Biosystems Inc , - , - , No.

Techniques: Biomarker Discovery, Sequencing, Multiplex Assay, Flow Cytometry, Luminex, Microarray, Genotyping Assay, Hybridization

Journal: RNA and DNA Diagnostics

Article Title: Microarrays as Research Tools and Diagnostic Devices

doi: 10.1007/978-3-319-17305-4_13

Figure Lengend Snippet: Basic principle of a DNA microarray. On the left side, the readout of a diagnostic microarray is shown using two-color labeling , representing two samples to be compared, used, e.g., in transcriptional profiling. Cy3- and Cy5-labeled target cDNAs are hybridized to their specific probes on the array as indicated on the left side . The schematic overview on the right side shows a typical hybridization using a competitive two-color (Cy3 and Cy5) hybridization in transcriptional profiling experiments. Targets present only in one sample result in either green or red signals, and targets present equally in both samples result in a yellow signal. The ratio between the red and green signal gives the difference in mRNA levels in the different samples

Article Snippet: Greiner Bio One International AG also offers CE-IVD certified microarray test kits.

Techniques: Microarray, Diagnostic Assay, Labeling, Hybridization